Terms: = Lung cancer AND RAF1, Raf-1, 5894, P04049, ENSG00000132155, c-Raf, CRAF
261 results:
1. Characterization of
Watanabe H; Inoue Y; Karayama M; Yazawa S; Mochizuka Y; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Enomoto N; Fujisawa T; Shinmura K; Inui N; Suda T
JCO Precis Oncol; 2024 Apr; 8():e2300538. PubMed ID: 38662982
[TBL] [Abstract] [Full Text] [Related]
2. RNF115 aggravates tumor progression through regulation of CDK10 degradation in thyroid carcinoma.
Zhu J; Guo L; Dai H; Zheng Z; Yan J; Liu J; Zhang S; Li X; Sun X; Zhao Q; Xu C
Cell Biol Toxicol; 2024 Feb; 40(1):14. PubMed ID: 38376606
[TBL] [Abstract] [Full Text] [Related]
3. Sex differences in the tumor promoting effects of tobacco smoke in a craf transgenic lung cancer disease model.
Zhong S; Borlak J
Arch Toxicol; 2024 Mar; 98(3):957-983. PubMed ID: 38245882
[TBL] [Abstract] [Full Text] [Related]
4. Targeting craf kinase in anti-cancer therapy: progress and opportunities.
Wang P; Laster K; Jia X; Dong Z; Liu K
Mol Cancer; 2023 Dec; 22(1):208. PubMed ID: 38111008
[TBL] [Abstract] [Full Text] [Related]
5. ITPR1-AS1 promotes small cell lung cancer metastasis by facilitating P21
Zhang Q; Zheng L; Bai Y; Su C; Che Y; Xu J; Sun K; Ni J; Huang L; Shen Y; Jia L; Xu L; Yin R; Li M; Hu J
Cancer Lett; 2023 Nov; 577():216426. PubMed ID: 37820992
[TBL] [Abstract] [Full Text] [Related]
6. CDK10 suppresses metastasis of lung adenocarcinoma through inhibition of the ETS2/c-raf/p-MEK/p-ERK signaling loop.
Zhang X; Zhao Y; Yiminniyaze R; Zhu N; Zhang Y; Wumaier G; Xia J; Dong L; Zhou D; Wang J; Li C; Zhang Y; Li S
Mol Carcinog; 2024 Jan; 63(1):61-74. PubMed ID: 37737453
[TBL] [Abstract] [Full Text] [Related]
7. Sex disparities in non-small cell lung cancer: mechanistic insights from a craf transgenic disease model.
Zhong S; Borlak J
EBioMedicine; 2023 Sep; 95():104763. PubMed ID: 37625265
[TBL] [Abstract] [Full Text] [Related]
8. Gain-of-function mutations in the catalytic domain of
Zhang J; Yang T; Han M; Wang X; Yang W; Guo N; Ren Y; Cui W; Li S; Zhao Y; Zhai X; Jia L; Yang J; Wu C; Wang L
Sci Adv; 2023 Jun; 9(22):eadc9273. PubMed ID: 37256945
[TBL] [Abstract] [Full Text] [Related]
9. Decoding the key compounds and mechanism of Shashen Maidong decoction in the treatment of lung cancer.
Cai J; Chen Y; Wang K; Li Y; Wu J; Yu H; Li Q; Wu Q; Meng W; Wang H; Lu A; Huang M; Wei G; Guan D
BMC Complement Med Ther; 2023 May; 23(1):158. PubMed ID: 37189139
[TBL] [Abstract] [Full Text] [Related]
10. SODD Promotes lung cancer Tumorigenesis by Activating the PDK1/AKT and RAF/MEK/ERK Signaling.
Bao F; An S; Yang Y; Xu TR
Genes (Basel); 2023 Mar; 14(4):. PubMed ID: 37107587
[TBL] [Abstract] [Full Text] [Related]
11. Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in
de Braud F; Dooms C; Heist RS; Lebbe C; Wermke M; Gazzah A; Schadendorf D; Rutkowski P; Wolf J; Ascierto PA; Gil-Bazo I; Kato S; Wolodarski M; McKean M; Muñoz Couselo E; Sebastian M; Santoro A; Cooke V; Manganelli L; Wan K; Gaur A; Kim J; Caponigro G; Couillebault XM; Evans H; Campbell CD; Basu S; Moschetta M; Daud A
J Clin Oncol; 2023 May; 41(14):2651-2660. PubMed ID: 36947734
[TBL] [Abstract] [Full Text] [Related]
12. Multiomics analysis revealed the mechanisms related to the enhancement of proliferation, metastasis and EGFR-TKI resistance in EGFR-mutant LUAD with ARID1A deficiency.
Sun D; Feng F; Teng F; Xie T; Wang J; Xing P; Qian H; Li J
Cell Commun Signal; 2023 Mar; 21(1):48. PubMed ID: 36869329
[TBL] [Abstract] [Full Text] [Related]
13. Rare molecular subtypes of lung cancer.
Harada G; Yang SR; Cocco E; Drilon A
Nat Rev Clin Oncol; 2023 Apr; 20(4):229-249. PubMed ID: 36806787
[TBL] [Abstract] [Full Text] [Related]
14. α4-α5 Helices on Surface of KRAS Can Accommodate Small Compounds That Increase KRAS Signaling While Inducing CRC Cell Death.
Abuasaker B; Garrido E; Vilaplana M; Gómez-Zepeda JD; Brun S; Garcia-Cajide M; Mauvezin C; Jaumot M; Pujol MD; Rubio-Martínez J; Agell N
Int J Mol Sci; 2023 Jan; 24(1):. PubMed ID: 36614192
[TBL] [Abstract] [Full Text] [Related]
15. PAK and PI3K pathway activation confers resistance to KRAS
Chan CH; Chiou LW; Lee TY; Liu YR; Hsieh TH; Yang CY; Jeng YM
Br J Cancer; 2023 Jan; 128(1):148-159. PubMed ID: 36319849
[TBL] [Abstract] [Full Text] [Related]
16. Estimated sensitivity profiles of lung cancer specific uncommon BRAF mutants towards experimental and clinically approved kinase inhibitors.
Mullaguri SC; Akula S; Ashireddygari VR; Sahoo PS; Burra VLSP; Silveri R; Mupparapu V; Korikani M; Amanchi NR; Subramanian J; Kancha RK
Toxicol Appl Pharmacol; 2022 Oct; 453():116213. PubMed ID: 36049549
[TBL] [Abstract] [Full Text] [Related]
17. USP7 regulates the ERK1/2 signaling pathway through deubiquitinating raf-1 in lung adenocarcinoma.
Park HB; Hwang S; Baek KH
Cell Death Dis; 2022 Aug; 13(8):698. PubMed ID: 35948545
[TBL] [Abstract] [Full Text] [Related]
18. Novel ALK-EML4 fusion with prominent mucous and hyaline stroma: Expanding the molecular genetic spectrum of S100 and CD34 positive spindle cell tumor.
Sun R; Hu R; Xiong J; Wang Y
Indian J Pathol Microbiol; 2022; 65(3):695-698. PubMed ID: 35900506
[TBL] [Abstract] [Full Text] [Related]
19. Circ_CDR1as: A circular RNA with roles in the carcinogenesis.
Ghafouri-Fard S; Khoshbakht T; Hussen BM; Sarfaraz S; Taheri M; Ayatollahi SA
Pathol Res Pract; 2022 Aug; 236():153968. PubMed ID: 35667198
[TBL] [Abstract] [Full Text] [Related]
20. Design, synthesis and anticancer activity of novel 2-arylbenzimidazole/2-thiopyrimidines and 2-thioquinazolin-4(3H)-ones conjugates as targeted RAF and VEGFR-2 kinases inhibitors.
Ali IH; Abdel-Mohsen HT; Mounier MM; Abo-Elfadl MT; El Kerdawy AM; Ghannam IAY
Bioorg Chem; 2022 Sep; 126():105883. PubMed ID: 35636123
[TBL] [Abstract] [Full Text] [Related]
[Next]
